WO2006028839A3 - Delta 6-desaturase genes and uses thereof - Google Patents

Delta 6-desaturase genes and uses thereof Download PDF

Info

Publication number
WO2006028839A3
WO2006028839A3 PCT/US2005/030945 US2005030945W WO2006028839A3 WO 2006028839 A3 WO2006028839 A3 WO 2006028839A3 US 2005030945 W US2005030945 W US 2005030945W WO 2006028839 A3 WO2006028839 A3 WO 2006028839A3
Authority
WO
WIPO (PCT)
Prior art keywords
desaturase
delta
conversion
acid
fatty acids
Prior art date
Application number
PCT/US2005/030945
Other languages
French (fr)
Other versions
WO2006028839A2 (en
Inventor
Pradip Murkerji
Yung-Sheng Huang
Amanda E Leonard
Suzette L Pereira
Jennifer M Thurmond
Original Assignee
Abbott Lab
Pradip Murkerji
Yung-Sheng Huang
Amanda E Leonard
Suzette L Pereira
Jennifer M Thurmond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Pradip Murkerji, Yung-Sheng Huang, Amanda E Leonard, Suzette L Pereira, Jennifer M Thurmond filed Critical Abbott Lab
Priority to BRPI0514783-2A priority Critical patent/BRPI0514783A/en
Priority to JP2007530304A priority patent/JP5616571B2/en
Priority to EP05806616A priority patent/EP1802747A2/en
Priority to AU2005282793A priority patent/AU2005282793B2/en
Priority to CA002578049A priority patent/CA2578049A1/en
Publication of WO2006028839A2 publication Critical patent/WO2006028839A2/en
Publication of WO2006028839A3 publication Critical patent/WO2006028839A3/en
Priority to NO20071180A priority patent/NO20071180L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)

Abstract

The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 6 (i.e., 'Δ6-desaturase'). In particular, Δ6-desaturase may be utilized, for example, in the conversion of linoleic acid to Ϝ-linolenic acid and in the conversion of α-linolenic acid stearidonic acid. The polyunsaturated fatty acids produced by use of the enzyme may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.
PCT/US2005/030945 2004-09-01 2005-08-30 Delta 6-desaturase genes and uses thereof WO2006028839A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BRPI0514783-2A BRPI0514783A (en) 2004-09-01 2005-08-30 delta 6 desaturase genes and their uses
JP2007530304A JP5616571B2 (en) 2004-09-01 2005-08-30 Δ6-desaturase gene and use thereof
EP05806616A EP1802747A2 (en) 2004-09-01 2005-08-30 Delta 6-desaturase genes and uses thereof
AU2005282793A AU2005282793B2 (en) 2004-09-01 2005-08-30 Delta 6-desaturase genes and uses thereof
CA002578049A CA2578049A1 (en) 2004-09-01 2005-08-30 Delta 6-desaturase genes and uses thereof
NO20071180A NO20071180L (en) 2004-09-01 2007-03-02 Delta 6 desaturase genes and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/931,626 US7456270B2 (en) 2004-09-01 2004-09-01 Δ6-desaturase genes and uses thereof
US10/931,626 2004-09-01

Publications (2)

Publication Number Publication Date
WO2006028839A2 WO2006028839A2 (en) 2006-03-16
WO2006028839A3 true WO2006028839A3 (en) 2007-01-25

Family

ID=35945070

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/030945 WO2006028839A2 (en) 2004-09-01 2005-08-30 Delta 6-desaturase genes and uses thereof

Country Status (8)

Country Link
US (2) US7456270B2 (en)
EP (1) EP1802747A2 (en)
JP (1) JP5616571B2 (en)
AU (1) AU2005282793B2 (en)
BR (1) BRPI0514783A (en)
CA (1) CA2578049A1 (en)
NO (1) NO20071180L (en)
WO (1) WO2006028839A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456270B2 (en) 2004-09-01 2008-11-25 Abbott Laboratories Δ6-desaturase genes and uses thereof
US7470532B2 (en) * 2005-10-19 2008-12-30 E.I. Du Pont De Nemours And Company Mortierella alpina C16/18 fatty acid elongase
US8795744B2 (en) * 2005-11-18 2014-08-05 Commonwealth Scientific And Industrial Research Organisation Feedstuffs for aquaculture comprising stearidonic acid
AU2008203869B2 (en) * 2007-01-03 2013-07-11 Monsanto Technology, Llc Food compositions incorporating additional long chain fatty acids

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304049A2 (en) * 1987-08-19 1989-02-22 Idemitsu Petrochemical Co. Ltd. Method for the production of lipids containing bis-homo-linolenic acid
EP0843972A1 (en) * 1996-11-20 1998-05-27 N.V. Nutricia Nutritional composition comprising fats for the treatment of the metabolic syndrome
WO2000020602A2 (en) * 1998-10-05 2000-04-13 Abbott Laboratories Delta 6 and delta 12 desaturases and modified fatty acid biosynthesis and products produced therefrom
US6340705B1 (en) * 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
US20020108147A1 (en) * 1991-10-10 2002-08-08 Thomas Terry L. Production of gamma linolenic acid by a delta6-desaturase

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982001011A1 (en) 1980-09-24 1982-04-01 Corp Cetus Diagnostic method and probe
EP0084796B1 (en) 1982-01-22 1990-05-02 Cetus Corporation Hla typing method and cdna probes used therein
US4582788A (en) * 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4683194A (en) * 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4943674A (en) * 1987-05-26 1990-07-24 Calgene, Inc. Fruit specific transcriptional factors
US5420034A (en) * 1986-07-31 1995-05-30 Calgene, Inc. Seed-specific transcriptional regulation
GB8507058D0 (en) * 1985-03-19 1985-04-24 Efamol Ltd Pharmaceutical & dietary compositions
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
GB8524276D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US5107065A (en) * 1986-03-28 1992-04-21 Calgene, Inc. Anti-sense regulation of gene expression in plant cells
US5188958A (en) * 1986-05-29 1993-02-23 Calgene, Inc. Transformation and foreign gene expression in brassica species
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5004863B2 (en) * 1986-12-03 2000-10-17 Agracetus Genetic engineering of cotton plants and lines
US5416011A (en) * 1988-07-22 1995-05-16 Monsanto Company Method for soybean transformation and regeneration
US5116871A (en) * 1988-09-13 1992-05-26 Efamol Holdings Plc Fatty acid therapy and compositions for the treatment of myalgic encephalomyelitis
US5231020A (en) * 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5106739A (en) * 1989-04-18 1992-04-21 Calgene, Inc. CaMv 355 enhanced mannopine synthase promoter and method for using same
US5175095A (en) * 1989-07-19 1992-12-29 Calgene, Inc. Ovary-tissue transcriptional factors
DE69103753T3 (en) * 1990-05-25 2008-01-24 E.I. Dupont De Nemours And Co., Wilmington NUCLEOTIDE SEQUENCE OF THE GENE FOR STEAROYL ACP DESATURASE FROM SOY.
US5518908A (en) * 1991-09-23 1996-05-21 Monsanto Company Method of controlling insects
PH31293A (en) * 1991-10-10 1998-07-06 Rhone Poulenc Agrochimie Production of y-linolenic acid by a delta6-desaturage.
AU675923B2 (en) 1991-12-04 1997-02-27 E.I. Du Pont De Nemours And Company Fatty acid desaturase genes from plants
US5912120A (en) * 1992-04-09 1999-06-15 The United States Of America As Represented By The Department Of Health And Human Services, Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism
WO1994011516A1 (en) 1992-11-17 1994-05-26 E.I. Du Pont De Nemours And Company Genes for microsomal delta-12 fatty acid desaturases and related enzymes from plants
EP0686197B1 (en) * 1993-02-26 2000-06-07 Calgene LLC Geminivirus-based gene expression system
AU692841B2 (en) * 1994-03-09 1998-06-18 Abbott Laboratories Transgenic animals producing oligosaccharides and glycoconjugates
NZ279676A (en) 1994-03-09 1998-04-27 Abbott Lab Humanized milk produced by non-human transgenic mammal transformed with a heterologous gene coding for human enzyme producing human oligosaccharides and glycoconjugates
US5750176A (en) * 1994-03-09 1998-05-12 Abbott Laboratories Transgenic non-human mammal milk comprising 2'-fucosyl-lactose
US5631152A (en) * 1994-10-26 1997-05-20 Monsanto Company Rapid and efficient regeneration of transgenic plants
US5654402A (en) 1994-10-26 1997-08-05 Michigan State University Methods and compositions relating to plant Δ6 palmitoyl-acyl carrier protein desaturase
US5968809A (en) * 1997-04-11 1999-10-19 Abbot Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
US7456270B2 (en) 2004-09-01 2008-11-25 Abbott Laboratories Δ6-desaturase genes and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304049A2 (en) * 1987-08-19 1989-02-22 Idemitsu Petrochemical Co. Ltd. Method for the production of lipids containing bis-homo-linolenic acid
US20020108147A1 (en) * 1991-10-10 2002-08-08 Thomas Terry L. Production of gamma linolenic acid by a delta6-desaturase
EP0843972A1 (en) * 1996-11-20 1998-05-27 N.V. Nutricia Nutritional composition comprising fats for the treatment of the metabolic syndrome
WO2000020602A2 (en) * 1998-10-05 2000-04-13 Abbott Laboratories Delta 6 and delta 12 desaturases and modified fatty acid biosynthesis and products produced therefrom
US6340705B1 (en) * 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN HUNG-CHANG ET AL: "Screening of microbes for the production of polyunsaturated fatty acids", JOURNAL OF THE CHINESE AGRICULTURAL CHEMICAL SOCIETY, vol. 32, no. 1, 1994, pages 33 - 46, XP008065230, ISSN: 0578-1736 *
PEREIRA S L ET AL: "Recent advances in the study of fatty acid desaturases from animals and lower eukaryotes", PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, CHURCHILL LIVINGSTONE MEDICAL JOURNALS,, GB, vol. 68, no. 2, February 2003 (2003-02-01), pages 97 - 106, XP002298342, ISSN: 0952-3278 *

Also Published As

Publication number Publication date
EP1802747A2 (en) 2007-07-04
BRPI0514783A (en) 2008-06-24
AU2005282793B2 (en) 2011-07-07
CA2578049A1 (en) 2006-03-16
US7456270B2 (en) 2008-11-25
JP2008511333A (en) 2008-04-17
US8778632B2 (en) 2014-07-15
US20090148919A1 (en) 2009-06-11
NO20071180L (en) 2007-05-31
AU2005282793A1 (en) 2006-03-16
JP5616571B2 (en) 2014-10-29
US20060048244A1 (en) 2006-03-02
WO2006028839A2 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
WO2002090493A3 (en) Δ4-desaturase genes and uses thereof
WO2002081668A3 (en) Desaturase genes and uses thereof
WO2000040705A3 (en) Human desaturase gene and uses thereof
WO2002008401A3 (en) Elongase genes and uses thereof
WO2000012720A3 (en) Elongase genes and uses thereof
ATE402944T1 (en) DESATURA BLENDS, ENZYMES ENCODED BY THEM AND USES THEREOF
WO2003102138A3 (en) Elongase genes and uses thereof
WO2005047485A3 (en) Delta12 desaturases suitable for altering levels of polyunsaturated fatty acids in oleaginous yeast
WO2005047480A3 (en) Delta-15 desaturases suitable for altering levels of polyunsaturated fatty acids in oleaginous plants and yeast
EP2357244A3 (en) Synthesis of long-chain polyunsaturated fatty acids by recombinant cells.
WO2004104167A3 (en) A δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
WO2007136762A3 (en) Production of fatty acids and derivatives thereof
WO2003078639A3 (en) Transgenic plants expressing enzymes involved in fatty acid biosynthesis
WO2007017419A3 (en) Method for producing arachidonic acid and/or eicosapentaenoic acid in useful transgenic plants
WO2006124598A3 (en) Biomass hydrolysate and uses and production thereof
WO2003099216A3 (en) Fatty acid desaturases from fungi
EP2840131A3 (en) Production of fatty acids and derivatives thereof
WO2006079567A3 (en) Brassica plant comprising a mutant fatty acid desaturase
WO2007051577A3 (en) METHOD FOR THE PRODUCTION OF γ-LINOLENIC ACID AND/OR STEARIDONIC ACID IN TRANSGENIC BRASSICACEAE AND LINACEAE
WO2008064096A3 (en) Elongase gene and uses thereof
WO2004029186A3 (en) Conjugated linoleic acid compositions
WO2003074716A3 (en) Methods for the production of unsaturated fatty acids
WO2006028839A3 (en) Delta 6-desaturase genes and uses thereof
MY159390A (en) Nutritional composition for infants
WO2009025372A1 (en) Composition containing reduced coenzyme q10, and method for stabilizing the composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005282793

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2578049

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/002432

Country of ref document: MX

Ref document number: 2007530304

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005282793

Country of ref document: AU

Date of ref document: 20050830

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005282793

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005806616

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005806616

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0514783

Country of ref document: BR